Exploiting the power of bile acid modulation to pursue new potential treatment options to improve the lives of people living with liver disease.
Our programs are designed to target and enable normal bile acid level modulation and treat diseases and disorders associated with irregularities in bile acid biology.
We are developing odevixibat initially to treat patients with PFIC, a rare genetic liver disease.
We leverage our expertise in bile acid modulation with the goal of bringing potentially transformative medicines to patients. For more information, read Albireo's Corporate Backgrounder.